Update on medical treatment for Cushing’s disease

Daniel Cuevas-Ramos1, Dawn Shao Ting Lim2 and Maria Fleseriu2*

Abstract
Cushing’s disease (CD) is the most common cause of endogenous Cushing’s syndrome (CS). The goal of treatment is to rapidly control cortisol excess and achieve long-term remission, to reverse the clinical features and reduce long-term complications associated with increased mortality. While pituitary surgery remains first line therapy, pituitary radiotherapy and bilateral adrenalectomy have traditionally been seen as second-line therapies for persistent hypercortisolism. Medical therapy is now recognized to play a key role in the control of cortisol excess. In this review, all currently available medical therapies are summarized, and novel medical therapies in phase 3 clinical trials, such as osilodrostat and levoketoconazole are discussed, with an emphasis on indications, efficacy and safety. Emerging data suggests increased efficacy and better tolerability with these novel therapies and combination treatment strategies, and potentially increases the therapeutic options for treatment of CD. New insights into the pathophysiology of CD are highlighted, along with potential therapeutic applications. Future treatments on the horizon such as R-roscovitine, retinoic acid, epidermal growth factor receptor inhibitors and somatostatin-dopamine chimeric compounds are also described, with a focus on potential clinical utility.

Keywords: Hypercortisolemia, Cushing’s disease, Pasireotide, Mifepristone, Ketoconazole, Osilodrostat, Levoketoconazole

Abbreviations: ACTH, Adrenocorticotropic hormone; CD, Cushing’s disease; CS, Cushing’s syndrome; CYP3A, Cytochrome P450 3A; D2R, Dopamine type 2 receptor; DPP-4, Dipeptidyl peptidase 4; EGFR, Epidermal growth factor receptor; GABA, Gamma-amino butyric acid; GLP-1, Glucagon-like peptide-1; GR, Glucocorticoid receptor; LAR, Long-acting repeatable; MC2R, Melanocortin type 2 receptor; MRI, Magnetic resonance imaging; POMC, Proopiomelanocortin; PPAR-gamma, Peroxisome proliferator-activated receptor gamma; sc, Subcutaneous; SEISMIC, Study of the efficacy and safety of mifepristone in the treatment of endogenous Cushing’s syndrome; SRL, Somatostatin receptor ligand; SSTR, Somatostatin receptor; USP8, Ubiquitin specific peptidase eight

Background
In 1932, Harvey Cushing described a syndrome characterized by serious manifestations consequent to systemic effects of chronic exposure to cortisol “…which has been found at autopsy in 6 out of 8 to be associated with a pituitary adenoma…” [1]. Cushing’s syndrome (CS) results from chronic, excessive exposure to glucocorticoids, the source of which may be either exogenous or endogenous. The most common cause (70 %) of endogenous cortisol production is Cushing’s disease (CD) due to overproduction of adrenocorticotropic hormone (ACTH) by a pituitary corticotroph adenoma [2, 3]. ACTH, in turn, stimulates melanocortin type 2 receptor (MC2R) at the adrenal cortex and increases cortisol synthesis [4, 5]. CD is more frequently observed in women, and in about 90 % of cases, is due to a pituitary microadenoma or corticotroph hyperplasia. Once ACTH-dependent glucocorticoid excess is confirmed, further tests are used to clarify the source of ACTH secretion [2, 6, 7]. Magnetic resonance imaging (MRI) may confirm the presence of a pituitary adenoma, however, in up to 40 % of cases, an adenoma remains undetectable [8, 9]. When a lesion is not visible or appears smaller than 6 mm on imaging, bilateral inferior petrosal sinus sampling is recommended to clearly distinguish between CD and ectopic ACTH production [6].
The goals of treating CD are to eliminate the source of ACTH excess, achieve biochemical eucortisolism and long-term remission, to reverse clinical features, reduce long-term complications and mortality, and improve quality of life [10]. Surgical resection of the identified pituitary adenoma remains first line treatment in CD patients, however, remission rates are reported to be 65–90 % for those with microadenomas and less than 65 % for those with macroadenomas [11, 12]. While repeat pituitary surgery, pituitary radiotherapy or bilateral adrenalectomy have traditionally been used as adjuvant therapies in persistent hypercortisolism [3, 11, 13], medical treatment now plays an increasingly important role in CD management [7, 10, 14]. Novel therapeutic medications and strategies have recently emerged. Such medications are summarized in this review, with emphasis placed on indications, efficacy and safety. New medical treatments on the horizon for CD are described, with a focus on treatments with potential clinical utility in the near future.

**Indications for medical therapy**

Over the last 10 years, the armamentarium of drugs available for CD treatment has expanded significantly. Many drugs have been shown to decrease cortisol levels and improve the clinical syndrome, and a reduction in tumor volume has been observed with some [15]. Medical therapy should be considered in the following circumstances: 1) as adjuvant therapy for persistent hypercortisolism after surgery [10, 16]; 2) as a pre-operative treatment in severe cases, [17]; 3) treatment of acute and life-threatening hypercortisolism complications (i.e. sepsis, uncontrolled hypertension, severe hyperglycemia, heart failure, intractable hypokalemia and psychosis [18, 19]; 4) whilst awaiting the full treatment effects of radiotherapy [20]; and 5) as first-line treatment in patients with surgical contraindications, those who decline surgery, in whom no definite lesion is seen, or when tumor is in an unfavorable location [14].

**Medical treatments currently used in Cushing’s disease**

Medications currently used in the treatment of CD are classified according to their mechanism of action as adrenal steroidogenesis inhibitors, pituitary-directed drugs and glucocorticoid receptor antagonists [21] (Table 1).

**Adrenal steroidogenesis inhibitors**

Adrenal steroidogenesis inhibitors block cortisol synthesis by inhibiting multiple key enzymes involved in steroidogenesis. Cortisol levels decrease, but no effect is observed on the underlying corticotroph tumor. There are no prospective studies on the efficacy and safety of steroidogenesis inhibitors, and variability in study design and quality makes comparison of efficacy difficult [22, 23]. Currently, apart from metyrapone and ketoconazole, which are approved in the European Union (EU), steroidogenesis inhibitors are used as off-label therapy in most other countries. Cortisol excess may be rapidly controlled but the “escape phenomenon” is common and higher doses are needed in the long-term to achieve disease control. They are therefore most commonly used temporarily as pre-operative treatment in patients with severe complications from CS when rapid control is necessary, and as a bridging therapy after radiotherapy [14, 22, 24]. Two treatment approaches are used: “normalization” of cortisol and the “block and replace” strategy that involves complete blockage of cortisol production and replacement with physiological doses of glucocorticoids.

Because of their effects on hepatic cytochrome P450 expression, drug interactions are commonly seen with adrenal steroidogenesis inhibitors. There is also limited experience with these medications during pregnancy and as Cushing’s disease affects mostly women of reproductive age, caution is advised in women planning pregnancy. Individual drug dosing, frequency and adverse effects are summarized in Table 1.

**Ketoconazole**

Ketoconazole is an imidazole derivative first used as an anti-fungal therapy. It was noted, however, that patients developed adrenal insufficiency at high doses. Ketoconazole inhibits steroidogenesis by blocking cholesterol side-chain cleavage complex, 17,20-lyase, 11beta-hydroxylase and 17 alpha-hydroxylase enzymes [25]. It has been postulated that ketoconazole also has an inhibitory effect on corticotroph ACTH secretion, though this remains debatable [26]. In the largest retrospective study to date (FReSKO), 200 patients received ketoconazole at doses of 200–1200 mg daily for pre-operative, primary and secondary treatment of CD. At last follow-up (mean 20.6 months), about half achieved normal urine free cortisol (UFC) levels and an additional 26 % had a ≥ 50 % decrease, associated with clinical improvement. Escape from treatment however, was demonstrated in 23 % of those with initial response [27]. Of note, like in previous reports, intolerability resulted in treatment cessation in approximately one-fifth of patients. Though generally reversible upon drug withdrawal, up to 5-fold increases in liver enzymes were found in 13.5 % of patients while severe hepatotoxicity (>5-fold elevation) was observed in 2.5 %. It is recommended that liver function be closely monitored during treatment with ketoconazole and dose reduction or discontinuation is advised when liver enzymes are 3-fold elevated [10]. More
recently, use of ketoconazole as a combination therapy has been studied (see below).

Fluconazole
Fluconazole was found in in vitro studies to inhibit cortisol production in human adrenocortical cells via inhibition of 17-hydroxylase and 11-beta hydroxylase. The effect was shown to be dose-dependent; potency was lower than ketoconazole. Though potentially promising and with less risk for hepatotoxicity, there are few reports of fluconazole use demonstrating clinical efficacy [28, 29].

Metyrapone
This steroidogenesis inhibitor primarily blocks 11-beta hydroxylase, as well as the cholesterol side chain cleavage complex, 17-alpha hydroxylase and 18-hydroxylase enzyme activities. Studies demonstrate normalization of cortisol secretion in 45–75 % of patients [17, 30, 31]. In the largest and most recent multicenter retrospective study to date, 195 patients with CS (59 % CD) were treated with metyrapone for a mean duration of 8 months. The majority was being treated pre-operatively for control of severe CS; 35 patients were on combination therapy. In patients on monotherapy, 55 %, 46–76 %, and 43 % of patients achieved biochemical control as assessed by a normal cortisol day curve, morning cortisol and UFC, respectively. Longer-term data (mean 18 months) available for 38 patients showed biochemical eucortisolism in 72 % [32].

Overall, escape has been reported in up to 19 % of patients with an initial response [14]. In addition, ACTH levels frequently increase and may drive androgen and mineralocorticoid overproduction, causing multiple adverse events (Table 1). Mineralocorticoid overproduction occurs due to 11-beta hydroxylase inhibition and accumulation of aldosterone precursors. To avoid mineralocorticoid-related adverse events, metyrapone is therefore often used in the short-term, for pre-operative control and in severe CD in combination with ketoconazole [33], though cases of long-term use have been reported [34].

Table 1 Medical therapy for Cushing’s disease

| Classification | Drug name | Dose | Possible adverse events; Close monitoring is necessary for all drugs |
|----------------|-----------|------|---------------------------------------------------------------|
| Steroidogenesis inhibitors | Ketoconazole | Oral 200–1200 mg/day; 1–3 times a day | Hepatitis, gastrointestinal disturbances, gynecomastia, skin rash, adrenal insufficiency. |
| | Fluconazole | Oral 100–200 mg/day; 2 times a day | AEs similar to ketoconazole, not well studied |
| | Metyrapone | Oral 0.5–6 g/day; 4 times a day | Hirsutism, acne, hypertension, hypokalemia, edema, gastritis, nausea, adrenal insufficiency. |
| | Etomidate | IV bolus of 0.03 mg/kg followed by 0.02–0.08 mg/kg/h | Somnolence, myoclonus, nausea, vomiting, dystonic reactions, adrenal insufficiency. |
| | Mitotane | Oral 2–5 g/day; 3 times a day | Gastrointestinal disturbances, hepatitis, neurologic manifestations, gynecomastia, neutropenia, lipid disorders, adrenal insufficiency; teratogenic |
| | Osilodrostat | Oral 10–60 mg/day; phase III clinical trial: NCT 02180217 | Nausea, asthenia, diarrhea, adrenal insufficiency. Testosterone increase in women. |
| Levoketoconazole | Oral 400 mg/day; phase III clinical trial: NCT 01838551 | N/A. |
| Dopamine D2R agonists | Cabergoline | Oral 0.5–7 mg/week | Headache, nausea, dizziness, nasal congestion, hypotension, depression |
| SRLs | Pasireotidea | SC 300–1800 µg/day; 2 times a day | Hyperglycemia, diabetes, diarrhea, nausea, abdominal pain, cholelithiasis, QT prolongation |
| | Pasireotide LAR | IM 30–60 mg/month; phase III clinical trial | N/A. |
| GR antagonist | Mifepristonea | Oral 300–1200 mg/day; Once daily | Nausea, fatigue, headache, hypokalemia, arthralgia, vomiting, peripheral edema, hypertension, dizziness, adrenal insufficiency, PAECs, endometrial thickening, vaginal bleeding; termination of pregnancy. |
| CDK2/Cyclin E inhibitor | R-Roscovitine | Oral Phase II clinical trial; clinicaltrials.gov identifier: NCT02160730 | N/A. |
| Nuclear receptor ligand | Retinoic acid | Oral Phase II clinical trial; clinicaltrialsregister.eu number: 2008-006379-65 | N/A. |

d2R dopamine D2 receptor, SRL somatostatin receptor ligand, SC subcutaneous, IM intramuscular, LAR long-acting repeatable, PAECs progesterone-receptor modulator-associated endometrial changes

*aFDA approved
Etomidate
Similar to other adrenal-directed drugs, etomidate acts by blocking multiple enzymes involved in steroidogenesis such as side-chain cleavage complex, 17-hydroxylase, 11 beta-hydroxylase, 17–20 lyase enzymes and aldosterone synthase [35]. After intravenous administration, a rapid and significant suppression of serum cortisol levels is seen within 5 h and maximal suppression occurs at 11 h [36–39]. Etomidate is therefore used to rapidly control severe manifestations of CS such as psychotic crises, severe sepsis or hypertension, in patients who are not immediate surgical candidates and are unable to tolerate oral medications [10, 40, 41]. Use of etomidate, however, should be limited to the intensive care setting, with close monitoring for central nervous system depression. Multiple regimens have been studied to block steroidogenesis whilst trying to avoid its anesthetic effects. Various approaches for complete and partial blockade also exist [40–42]. Guidelines published by the Endocrine Society suggest a loading dose followed by a weight-based continuous infusion titrated to achieve serum cortisol levels between 10 and 20 μg/dL (280–560 nmol/L) [10]. It has, however, also been suggested that treatment targets in the intensive care setting be higher than in the non-acute setting at 18–30 μg/dL (500–800 nmol/L) [41]. Serum electrolytes and cortisol levels therefore need to be monitored every 4–6 h, to achieve target cortisol levels and to prevent adrenal insufficiency, which may require treatment with intravenous hydrocortisone (“block and replace” regimen) [14].

Mitotane
Mitotane (o,p'-diphenylmethane derivative agent) has both adrenostatic and adrenolytic actions, and is for this reason, most commonly used in the treatment of adrenocortical carcinoma. Mitotane blocks the cholesterol side-chain cleavage complex, 11 beta-hydroxylase, 18-hydroxylase and 3 beta-hydroxysteroid-dehydrogenase (HSD3B2) enzymes, reducing cortisol production [43]. Due to its slow onset of action, efficacy is delayed; therapeutic levels are achieved in up to 3 months. Remission rates up to 100 % have been reported, however, concomitant use of pituitary irradiation is likely to have confounded these results [14]. A single-center French retrospective study of 67 patients with CD demonstrated remission in 72 % after treatment for a median duration of 6.7 months. Adverse events were frequent, including gastrointestinal disturbance (50 %), impaired mentation and dizziness (30 %) [44]. Mitotane’s long half-life (up to 160 days) also results in significant circulating drug levels despite drug continuation [43]. Supraphysiological doses of hydrocortisone replacement are often necessary to treat adrenal insufficiency as mitotane increases cortisol-binding globulin (CBG) and activates cytochrome P450 3A4 CYP3A4, resulting in accelerated metabolism of exogenous steroids [45].

Pituitary-directed drugs
This group of medications acts directly on corticotroph adenomas to reduce ACTH secretion. Two currently available classes of medications that act centrally are dopamine type 2 receptor (D2R) agonists, and somatostatin receptor ligands (SRL). Dose regimens and adverse events are summarized in Table 1.

Dopamine D2 receptor agonists
About 80 % of corticotroph pituitary adenomas demonstrate D2R expression [46, 47]. The two available dopamine agonists are bromocriptine and cabergoline; studies have shown variable short- and long-term effectiveness and adverse effects of bromocriptine, thus limiting its use [14]. Small retrospective and open-label prospective studies in patients with persistent CD after surgery demonstrate biochemical response to cabergoline in up to 75 % of patients, though UFC normalization within 3–6 months has only been reported in 25–40 % [48–51]. The “escape phenomenon” is not uncommon, and reported in up to one-third; long-term control of cortisol secretion over 12–24 months was demonstrated in 30–40 % of patients on cabergoline at a median dose of 2–3.5 mg/week [49, 50]. Though it has been suggested that efficacy improves with higher cabergoline doses [49–51], no consistent dose-dependent reduction in cortisol levels was seen in a short-term prospective study of 20 patients on a median dose of 5 mg/week [52]. Tumor shrinkage is also rare, reported in 20 % of cases [50]. As the data regarding cabergoline’s efficacy is at present still limited, its use in the treatment of CD remains off-label [14]. Cabergoline is fairly well tolerated, and thus far, no significant association has been found between its use for the treatment of pituitary tumors and the development of clinically significant cardiac valve disease [53].

Somatostatin receptor ligands (SRL)
Somatostatin inhibits ACTH synthesis and secretion. Corticotroph adenomas commonly express somatostatin receptors (SSTR), mainly type 2 (SSTR2) and 5 (SSTR5) [54, 55]. However, hypercortisolism reduces expression of SSTR2, and classical SRLs that act mainly on SSTR2 (octreotide and lanreotide) have not been shown to be effective in patients with CD [56, 57]. Although decreasing cortisol levels may increase SSTR2 expression, this phenomenon occurs at the mRNA level. No increase of SSTR2 protein and receptor externalization has been noted [58]. Further research has led to the development of pasireotide, a multireceptor-targeted SRL
with high binding activity to SSTR5, and also to SSTR2, SSTR3 and SSTR1.

**Pasireotide**

In 2012, pasireotide became the first medical treatment to be approved by the European Medicines Association (EMA) and the United States Federal Drug Association (FDA), for the treatment of CD after unsuccessful pituitary surgery or when surgery is contraindicated. In a phase II, open-label, single-arm, multicenter pilot study, 76 % of patients had a reduction in UFC and 17 % achieved complete normalization when subcutaneous (sc) pasireotide was administered at 600 μg twice a day for 15 days. Reductions were also seen in serum cortisol and plasma ACTH levels [59]. This was followed by a phase III, double-blind, randomized clinical trial in which 162 patients were administered 600 or 900 μg of pasireotide twice daily, with dose escalations of 300 μg made after 3 months, depending on UFC response. At 6 months, UFC decreased in the majority; almost half had > 50 % reductions and 20 % achieved normal UFC without dose escalation. Response was rapid, with a median 50 % reduction of UFC in the first 2 months of treatment. Open-label extension through 12 months showed sustained UFC normalization in 13 % of patients in the 600 μg group and 25 % in the 900 μg group. Of note, patients with mild hypercortisolism at baseline had higher UFC normalization rates than patients with severe hypercortisolism [60]. Late-night salivary cortisol (LNSC) was also measured in 93 patients, and normalized in 37 and 19 % of patients who had raised baseline LNSC levels, at 6 and 12 months, respectively. A moderate correlation (r = 0.55) was found between LNSC and UFC measurements [61]. Significant improvement in clinical signs and symptoms was also seen at 12 months of treatment [62]. Additional data from an international expanded-access study also showed UFC normalization in about 40 % of patients who remained on treatment at 48 weeks [63]. In a clinical practice setting study, 48 % of patients with complete UFC normalization at 12 months remained controlled at 24 months, suggesting the possibility of treatment escape in the remainder. Of note, however, is that, despite this, clinical benefits, including blood pressure control and weight reduction were sustained [64]. Data from case reports and small case series suggest that in a limited population, treatment efficacy may extend beyond 5 years [65, 66]. More recently, 60-month follow-up data demonstrate that initial reductions in UFC and clinical improvement were maintained in patients who remained on treatment, suggesting that pasireotide may be effective as a long-term treatment in selected patients with CD [67]. Discontinuation rate was, however, high due to unsatisfactory therapeutic effect (32.7 %), adverse events (22.2 %), consent withdrawal (18.5 %) and administrative problems (9.9 %).

Tumor shrinkage has also been reported; about 9 and 44 % of patients on pasireotide 600 and 900 μg, respectively, showed tumor size reduction at 12 months, suggesting a dose-dependent effect [60]. More recently, significant (> 25 %) reductions in tumor volume and even tumor disappearance has also been observed [68]; tumor shrinkage was also reported in corticotroph macroadenomas on de novo treatment with pasireotide [69]. Therefore, in addition to its use in patients with persistent or recurrent CD after pituitary surgery, pasireotide may also be useful as first line therapy in macroadenomas to facilitate surgical resection.

With the exception of hyperglycemia incidence and severity, the safety profile of pasireotide is similar to other SRLs [60, 64, 70]. In the pivotal phase III study, hyperglycemia-related adverse events were documented in 73 %, the risk of which was higher in patients with pre-existing diabetes or impaired glucose tolerance. Hyperglycemia was observed soon after the initiation of pasireotide, but glucose and glycated hemoglobin levels stabilized after the initiation or escalation of glucose-lowering therapy. At the end of the study, 48 % of patients who did not have diabetes at baseline had glycated hemoglobin ≥ 6.5 % [60]. Reduction in insulin secretion and the incretin response have been demonstrated in healthy volunteers receiving pasireotide [71]. Metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors are therefore generally recommended as first and second line therapy, respectively for pasireotide-related hyperglycemia [72, 73]. Glucagon-like peptide-1 (GLP-1) agonists and insulin may also be required in cases of more severe glucose intolerance [71, 72, 74].

An intramuscular long-acting-release (LAR) formulation of pasireotide approved for the treatment of acromegaly is now being evaluated for use in CD. Pasireotide LAR was previously reported to be effective in reducing ACTH and tumor volume in a patient with Nelson’s syndrome and aggressive corticotroph tumor growth [75]. In a double-blind, randomized controlled phase III trial of 150 patients with persistent, recurrent or de novo CD, UFC normalization was observed in 40 % of patients treated with pasireotide LAR 10 or 30 mg monthly for a duration of 7 months. Median decrease in UFC was 48 % [76]. Safety profile was similar to that of twice-daily sc pasireotide. Hyperglycemia-related adverse events were noted in 68 and 80 % of patients in the 10 and 30 mg groups, respectively, which led to treatment discontinuation in only 5 patients. As pasireotide LAR is administered monthly, improved patient compliance is a potential advantage over sc pasireotide.

**Other regulators of the hypothalamus-pituitary-adrenal axis**

Serotonin antagonists and gamma-amino butyric acid (GABA) agonists are neuromodulatory drugs that have
Glucocorticoid receptor antagonists

Mifepristone

Mifepristone is a high-affinity, non-selective glucocorticoid receptor (GR) antagonist with ten and four times greater affinity to the GR compared to cortisol and dexamethasone, respectively [82, 83]. GR antagonism results in rapid control of the systemic effects of cortisol excess in patients with CS. ACTH, and subsequently cortisol levels increase due to a loss of negative feedback regulation [84–86]. Such parameters are therefore, not useful for monitoring treatment efficacy or disease activity. Instead, improvement in clinical and metabolic features of CS should be used to evaluate treatment efficacy [14, 87, 88].

Two studies have evaluated the efficacy and safety of mifepristone. In the first retrospective study, 20 patients with CS were treated with mifepristone; four had CD, 3 of whom had rapid improvement in clinical signs and symptoms [89]. Following this was a large prospective multicenter trial, Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing’s Syndrome (SEISMIC), which looked at the effects of 24 weeks of mifepristone (300–1200 mg/day) in 50 patients with CS, among whom 43 had CD [84]. In patients with diabetes mellitus or glucose intolerance, significant improvements in glucose profiles were observed in 60 %. Decrease in body weight, waist circumference and fat mass, and increases in insulin sensitivity were observed in 87 % of patients. Post-hoc analysis also demonstrated improvements in global clinical response assessments (based on glucose, lipid and blood pressure control, body composition, clinical appearance, strength, psychiatric/cognitive symptoms and quality of life parameters) in 88 % of patients at 24 weeks [90]. Of 27 patients who entered a long-term extension study (median treatment duration 11.3 months), a dose-dependent ≥2-fold increase in ACTH was observed in 72 %, which returned to baseline after drug discontinuation. Tumor progression was seen in four cases; three had macroadrenomas and in one patient, follow-up MRI demonstrated a microadenoma that was not previously detected at diagnosis [91]. Recently, maintenance of weight loss was demonstrated at 2 years follow-up [92]. Based on results of the SEISMIC study, the FDA, in 2012, approved mifepristone for the treatment of patients with endogenous CS who have failed surgery or are not surgical candidates and have concomitant type 2 diabetes mellitus or glucose intolerance [10].

The lack of biochemical parameters for monitoring treatment response to mifepristone is an important limitation especially with regard to assessment for adrenal insufficiency. Adrenal insufficiency was reported in 2 out of 50 patients in the SEISMIC study; another 5 patients were treated with dexamethasone for suspected adrenal insufficiency. Due to mifepristone’s long half-life and high affinity for the GR, supraphysiological doses of dexamethasone (2–8 mg daily in this study) are needed to overcome GR antagonism [22, 93]. High cortisol levels also have the potential to overwhelm renal inactivating enzyme 11 beta-hydroxysteroid dehydrogenase type 2. Subsequent mineralocorticoid receptor activation by excess cortisol results in hypertension, hypokalemia and edema, which often respond well to potassium replacement and mineralocorticoid receptor blockade with spironolactone [10, 84]. Additionally, due to its anti-progestin activity, mifepristone is contraindicated in pregnancy and in women with endometrial hyperplasia or carcinoma, or unexplained vaginal bleeding [14, 89, 94]. A recent case report suggested, however, no endometrial hyperplasia or proliferative changes in a patient with prolonged exposure to ulipristal, another selective progesterone receptor modulator [95]. Caution is also needed with concomitant use of CYP3A4 inhibitors such as ketoconazole, which may increase mifepristone levels, and drugs that increase QT interval, such as pasireotide [94]. Other adverse events are summarized in Table 1.

Combination drug therapy for Cushing’s disease

As highlighted above, no single drug has demonstrated complete efficacy in the treatment of CD. Adverse events are also not uncommonly encountered in patients on medical therapy (Table 1). A strategy to increase treatment efficacy, whilst reducing doses of individual drugs and thereby minimizing adverse events, is to combine drugs with additive, synergistic, and/or complementary mechanisms of action.

Combination of adrenal steroidogenesis inhibitors

Of 62 patients with CS (84 % CD) treated pre-operatively with both ketoconazole (200–600 mg/day) and metyrapone (750–1000 mg/day), normalization of UFC was observed in 45 %. Median duration of treatment was 4 months [30]. This combination is also used in the treatment of severe CS when immediate surgery is contraindicated [10, 30, 33]. Additionally, use of 3 adrenal steroidogenesis inhibitors, ketoconazole (400–1200 mg/day), metyrapone (3.0–4.5 g/day) and mitotane (3.0–5.0 g/day), resulted in rapid normalization of UFC and clinical improvement in 11 patients with severe ACTH-dependent...
CS (4 CD). Ketoconazole and metyrapone were successfully discontinued in 7 patients after 3.5 months; UFC remained normal with mitotane monotherapy. There was, however, a high rate of adverse events with this triple-combination, with acute adrenal insufficiency being reported in 36% of patients, and liver enzyme elevation in up to 82% [96].

**Cabergoline and ketoconazole**

This treatment approach combines a pituitary-directed drug with an adrenal steroidogenesis inhibitor, therefore targeting both pituitary ACTH and adrenal cortisol synthesis. In a small series, the addition of very low-dose ketoconazole (50–200 mg/day) to cabergoline (3.5 mg/week) resulted in UFC normalization in six patients who had a partial response to cabergoline [97]. Thereafter, in a prospective study of 12 patients with persistent CD after pituitary surgery, the addition of ketoconazole to cabergoline increased rates of UFC normalization from an initial 25% with cabergoline alone (dose 2–3 mg/week), to 75% when 200–400 mg/day of ketoconazole was added. Amongst the six patients who benefitted from combination therapy, subsequent cabergoline dose reductions could be made in two patients [51]. Similar findings were demonstrated in a subsequent prospective analysis of 14 patients with persistent, recurrent or de novo CD: combination therapy with cabergoline doses of up to 3 mg/week and ketoconazole up to 600 mg/day resulted in UFC normalization in 79% of patients. Neither drug was effective as monotherapy, nor did the choice of starting treatment (cabergoline vs. ketoconazole) affect outcomes [98]. Of note, though combination therapy lowered late night salivary cortisol levels, they remained elevated, indicating persistent abnormal diurnal variation. Larger studies are needed to confirm these findings.

**Pasireotide, cabergoline and ketoconazole**

The combination of pasireotide, cabergoline and ketoconazole was studied in a prospective open-label study of 17 patients with CD. Patients were placed on sc pasireotide 100–250 μg 3 times/day at the start of the study. If no disease control was achieved at 28 days, cabergoline was added (0.5–1.5 mg every other day), and if UFC remained elevated at 60 days, ketoconazole 200 mg 3 times/day was added. This stepwise addition of first cabergoline, and then ketoconazole to pasireotide, increased UFC normalization rates from 29 to 53 to 88%, respectively at 80 days, with associated decreases in body weight, waist circumference and blood pressure [99]. Quality of life did not change significantly in the short term, but improved after 1 year of remission in three patients who continued medical therapy [100]. A large
Clinical trials

**Vitro half maximal inhibitory concentration (IC50) of 7.5 metyrapone, as demonstrated in preclinical studies (in vitro half maximal inhibitory concentration (IC50) of 7.5 nM vs 2.5 nM for metyrapone) [103]. In addition, its longer half-life allows twice daily oral administration, conferring an advantage over metyrapone, which may require administration up to 6 times daily [103, 104]. In a 10-week proof of concept study (LINC-1; NCT01331239), osilodrostat demonstrated good efficacy, normalizing UFC in 11 of 12 patients with CD. Mean ACTH, 11-deoxycortisol and 11-deoxycorticosterone levels increased during treatment but declined after discontinuation [103]. The extension phase study enrolled 4/12 of the original cohort and an additional 15 new patients with CD with UFC more than 1.5 × upper limit of normal (ULN). Patients received 4–10 mg per day as a starting dose depending on the degree of UFC elevation. Doses were then adjusted every 2 weeks as needed to 10–60 mg/day until UFC normalized. UFC normalized in 78.9 % of patients at 22 weeks [105]. Adverse reactions were well tolerated, the most common of which were nausea, diarrhea and asthenia. Adrenal insufficiency and/or glucocorticoid withdrawal was reported in one-third of patients, highlighting the potency of osilodrostat and the need for slow and careful dose titration. Elevated testosterone levels, hirsutism and acne were observed in 3 of 11 females (Table 1). Importantly, no new safety signals were identified after 22 weeks of treatment. Interim analysis of the open-ended extension study (LINC-2) points to sustained long-term efficacy of osilodrostat. At 19 months, mean UFC and 0800 morning serum cortisol levels were within the normal range, an effect that had been observed since week 6. Overall response rate was 93.8 % at week 22 and at month 19, with no treatment escape noted in any patients. Improvement was noted in weight and body mass index (BMI) [106]. Based on these results, osilodrostat shows promise as an alternative treatment in CD [104] and two phase III studies (LINC-3 and LINC-4) are currently underway.

Recently, the combination of osilodrostat and pasireotide was evaluated in rats [107]. Acceptable safety and efficacy was shown and lend interest to future testing of this combination in clinical trials.

**Levoketoconazole (COR-003)**

Levoketoconazole is an investigational drug for CS that acts similarly to its enantiomer, ketoconazole (2S,4R and 2R,4S racemic mixture), but is hypothesized to provide better efficacy and safety. The (2S,4R) single enantiomer, levoketoconazole is 2 and 7 times more potent than ketoconazole in inhibiting 21-hydroxylase (CYP21) and 17 alpha-hydroxylase (CYP17), and 11 beta-hydroxylase (CYP11B1) steroidogenesis enzymes, respectively (Fig. 1). A recent pre-clinical study also confirmed a significantly higher potency in enzyme inhibition than its pure (2R, 4S) enantiomer. This theoretically leads to lower doses, and fewer adverse events [104].

Experiments in an animal model showed greater potency and efficacy in reducing serum cortisol. In a phase I study, when administered to healthy subjects, levoketoconazole (400 mg/day) reduced serum cortisol levels significantly by day 4, compared to placebo and ketoconazole. The drug was well tolerated; headache, back pain and nausea were the most frequently reported adverse events [108]. Being 12 times less potent than ketoconazole in inhibiting CYP7A1, less interference with bile acid synthesis and metabolite elimination, and therefore less hepatotoxicity, is anticipated [108]. Reduction of cholesterol and C-reactive protein have also been reported in patients with type 2 diabetes mellitus after short-term administration of levoketoconazole [109]. A phase III single-arm, open-label trial (clinicaltrials.gov; NCT01838551) is currently underway to evaluate the efficacy, safety, tolerability and pharmacokinetics of levoketoconazole in patients with CS [110].

**R-Roscovitine**

The cyclin-dependent kinase (CDK) and cyclin E inhibitor R-roscovitine has been evaluated as potential therapy for CD patients. R-roscovitine was first shown to be effective in reducing ACTH and serum corticosterone levels in a mouse model. Further studies demonstrated restraint of tumor growth after R-roscovitine treatment in a mouse model with xenografted ACTH-secreting pituitary tumor [111]. R-roscovitine induces corticotroph tumor cell cycle arrest. Its mechanism of action is still under study, and seems to be related to disruption of cyclin E2F1 binding to proopi melanocortin (POMC) gene promoter and suppression of corticotroph transcription factors, resulting in decreased ACTH expression (Fig. 1) [112]. Currently, a phase II clinical trial (clinicaltrials.gov;
with CD. Clinical trials are needed to evaluate its efficacy in patients than 40% of patients. Further randomized, double-blind, though mild and reversible, were encountered in more tions up to 52% seen in the rest [115]. Adverse events, i n 4 0 p a t i e n t s ( 2 5% ) a t 1 2 m o n t h s , w i t h U F C r e d u c - 

The chimeric compound BIM-23A760, which has high – - 

interact with both dopamine D2R and SSTRs have the 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-

selective, peptide MC2R antagonists are emerging therapies 

Medical treatments on the horizon 

Epidermal growth factor receptor (EGFR) inhibitors 

EGFR is expressed in the pituitary, but mainly in corticotroph adenomas, and plays an important role in tumorigenesis. Inhibition of ACTH secretion, reduction in tumor size and clinical improvement were observed in animal models treated with gefitinib, an EGFR tyrosine kinase inhibitor [116]. Recently, an additional mechanism by which EGFR plays a role in the pathophysiology of CD has been proposed, with potential therapeutic applications [117]. The ubiquitin-specific peptidase eight (USP8) gene was found to be mutated in 33–66% of patients with CD [118]. Mutations clustered around the 14-3-3 protein that enhances the catalytic ac-
**References**

1. Cushing H. The basophil adenomas of the pituitary body. Ann R Coll Surg Engl. 1966;44(1):180–1.

2. Newell-Price J, Bertagna X, Grossman AB, Sonino N, Stalla GK, Wass JA. Cushing's disease: a review of its endocrine, metabolic, and neuroendocrine consequences. J Clin Endocrinol Metab. 2014;99(5):1515–24. doi:10.1210/jc.2014-1767.

3. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing's syndrome. Endocrinol Metab Clin North Am. 2008;37(1):135–59. doi:10.1016/j.ecl.2007.10.010.

4. Cuevas-Ramos D, Fleseriu M. Medical treatment of Cushing's disease. Minerva Endocrinol. 2016;41(3):324–30. doi:10.17756/me.2015.41.3.324.

5. Lonser RR, Nieman LK, Oldfield EH. Cushing's disease: diagnosis and treatment. J Neurosurg. 2016;124(1):14–26. doi:10.3171/2015.5.JNS152119.

6. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Stalla GK, Wass JA. Cushing's disease: what is the state of the art? Endocrine. 2014;47(1):9–20. doi:10.1007/s12020-013-0129-2.

7. Colao A, Boscaro M, Derom C, Danuser FF. Managing Cushing's disease: the state of the art. Endocrinol Metab Clin North Am. 2004;33(2):553–60. doi:10.1016/j.ecl.2003.03-00871.

8. Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing's disease: a review of its pathophysiology and treatment. J Clin Endocrinol Metab. 2008;93(7):2454–62. doi:10.1210/jc.2007-2734.

9. Valassi E, Bilbao BM, Swearingen B, Beaudet AL, Chrousos GP, Fava GA, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Stalla GK. Cushing's disease: diagnosis and treatment. J Clin Endocrinol Metab. 2006;91(12):4146–60. doi:10.1210/jc.2006-0049.

10. Lambert SW, de Lange SA, Steffano S. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab. 1982;54(2):286–91. doi:10.1210/jcem-54-2-286.

11. Nieman LK, Bilbao BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(9):3087–111. doi:10.1210/jc.2015-01818.

12. Bilbao BM, Grossman AB, Stewert PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Harmus AR, Holfand LJ, Klubanski A, Lacroix A, Lindsey JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vence ML, Was J, Boscaro M. Treatment of adrenocorticotropic-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–62. doi:10.1210/jc.2007-2734.

13. Valassi E, Bilbao BM, Swearingen B, Beaudet AL, Chrousos GP, Fava GA, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Stalla GK. Cushing's disease: diagnosis and treatment. J Clin Endocrinol Metab. 2005;90(2):601–10. doi:10.1210/jc.2004-1672.

14. Tritos NA, Bilber BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7(5):279–89. doi:10.1038/nrendo.2011.12.

15. Fleseriu M, Petersenn S. Medical management of Cushing's disease: what is the future? Pituitary. 2012;15(S1):330–41. doi:10.1007/s11110-012-0397-5.
syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70(5):1426–30. doi:10.1210/clin-70-5-1426.

38. Greening JE, Brain CE, Perry LA, Mustafic I, Sales Marques J, Grossman AB, Savage MO. Efficient short-term control of hypercortisolaemia by low-dose etomotec in severe paediatric Cushing's disease. Horm Res. 2006;63(3):140–3. doi:10.1159/000088887.

39. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznik RH, Besser GM. Emergency and prolonged use of intravenous etomotec to control hypercortisolism in a patient with Cushing's syndrome and periitonitis. J Clin Endocrinol Metab. 1998;83(10):3542–4. doi:10.1210/jcem.83.10.35156.

40. Soh LM, Gunganah K, Akker SA, Jones P, Khachi H, Dodzo K, Drake WM. Etomotec in the emergency management of hypercortisolism. Eur J Endocrinol. 2012;167(3):727–8. doi:10.1530/EJE-12-0698. author reply 729.

41. Preda VA, Sen J, Karavitaki N, Grossman AB. Etomotec in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012;167(2):137–43. doi:10.1530/EJE-12-0274.

42. Zanerck KG, Kelly N, Peppard W, Herrmann D, Findling JW. Continuous Etomotec Infusion for the Management of Severe Hypercortisolism in ACTH-Dependent Cushing's Syndrome: A Case Series. Endocrine Society's 96th Annual Meeting and Expo. Chicago. 2014. SAT-0819.

43. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J, Gelderblom H. Mirtotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol. 2011;164(4):621–6. doi:10.1530/EJE-10-0956.

44. Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR, Stiel JN. The Dopamine D2 receptor gene expression and function in corticotroph pituitary adenomas. Endocrine. 2001;14(3):329–34. doi:10.1385/EN:14:3:329.

45. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Legmann P, Bertagna X, Bertherat J. Efficiency and tolerance of mitotane in Cushing's disease: results from a Phase III study of pasireotide in Cushing's disease. Eur J Endocrinol. 2011;164(4):621–6. doi:10.1530/EJE-12-0358.

46. Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smeir IR, Stiel JN. The effect of opr-D-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf). 1987;27(4):437–44.

47. Stefanou L, Kovacs K, Honvath E, Buchfelder M, Fahrbusch R, Lanaranjan L. Dopamine D2 receptor gene expression in human adenohypophyseal adrenomas. Endocrine. 2001;14(3):329–34. doi:10.1385/EN:14:3:329.

48. Ferone D, Pivonello C, Vitale G, Zatelli MC, Colao A, Pivonello R. Molecular basis of pharmacological therapy in Cushing's disease. Endocrine. 2014;46(2):181–98. doi:10.1007/s12021-013-0098-5.

49. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Anzivino M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW. Dopamine receptor expression and function in corticotrophic pituitary tumors. J Clin Endocrinol Metab. 2004;89(8):2452–62. doi:10.1210/jc.2003-030837.

50. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163(5):709–16. doi:10.1530/EJE-10-0382.

51. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–30. doi:10.1210/jc.2009-01038.

52. Villar L, Naves LA, Azevedo MF, Amuda MJ, Anahata CM, Moura ESL, Agra R, Pontes L, Montenegro L, Albuquerque JQ, Canas V. Effectiveness of cabergoline monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13(2):123–9. doi:10.1007/s11102-009-0209-8.

53. Burman P, Eden-Engstrom B, Ekman B, Karlsson FA, Schwarz E, Wahlberg J. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol. 2016;174(1):17–24. doi:10.1530/EJE-15-08070.

54. Auriera RS, Pivonello R, Feneri L, Piscitelli P, Colao A. Cabergoline use for pituitary tumors and valley disorders. Endocrinol Metab Clin North Am. 2015;44(1):88–97. doi:10.1016/j.ecl.2014.10.007.

55. van der Hoek J, Waaiers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab. 2005;289(2):E278–87. doi:10.1152/ajpendo.00044.2005.

56. Nielsen S, Mellemkjær S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeka J, Jorgensen JD. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest. 2001;24(6):430–7. doi:10.1007/BF03351043.

57. Cueva-Ramos et al. *Clinical Diabetes and Endocrinology* (2016) 2:16 Page 11 of 13

58. van der Hoek J, Waaiers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab. 2005;289(2):E278–87. doi:10.1152/ajpendo.00044.2005.

59. Nielsen S, Mellemkjær S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeka J, Jorgensen JD. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest. 2001;24(6):430–7. doi:10.1007/BF03351043.
hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab. 2013;39(3):14–30. doi:10.1016/j.diabet.2012.10.005.

73. Breitschaft A, Hu K, Hermosillo Resendez K, Darstein C, Golor G. Management of hyperglycaemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458–65. doi:10.1016/j.diabet.2013.12.011.

74. Colao A, De Block G, Gaztambide M.S, Kumar S, Seufather J, Casanueva F.F. Managing hyperglycaemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17(2):180–6. doi:10.1007/s11102-013-0483-3.

75. Katsnelson L. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson’s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab. 2013;98(5): 1803–7. doi:10.1210/jc.2013-1497.

76. Lacroix A, Petersenn S, Bilker BMK, et al. Monthly Pasireotide LAR Improves Urinary Free Cortisol (UFC) in Patients with Cushing’s Disease: Results from a Randomized, Double-Blind, Multicenter, Phase III Study. Pituitary Disorders - It’s Not the Anterior Pituitary (posters). Boston: 2016; SAT-546.

77. Sonino N, Fava GA, Fallo F, Franceschetti A, Belluardo P, Baudin E, Chanson P, Young J. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 2011;96(9):2796–804. doi:10.1210/jc.2011-0536.

78. Pavoniello R, De LM, De Martino MC. Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline. In: 11th European congress of endocrinology, Istanbul, Turkey. 2009.

79. Barbot M, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L, Mantero F, Scaroni F. Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary. 2014;17(2):109–17. doi:10.1007/s11102-013-0475-3.

80. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hoffand L. Lamberts WS. Pasireotide alone or with ketoconazole and cabergoline in Cushing’s disease. N Engl J Med. 2010;362(19):1846–8. doi:10.1056/NEJMoa1000994.

81. van der Pas R, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Webb SM, Lamberts WS, Hoffand L, Feelders RA. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease. Pitutary. 2013;16(4):536–44. doi:10.1007/s11102-012-0452-2.

82. Fleseriu M, Pavoniello R, Pedroncelli AM, et al. Study Design of a Phase II Trial of Subcutaneous Pasireotide Alone or Combined with Cabergoline in Patients with Cushing’s Disease. Prolactinoma and Acromegaly 2. Chicago: 2014; MON-0715.

83. Fleseriu M, Pavoniello R, Pedroncelli AM, et al. Study Design of a Phase II Trial of Subcutaneous Pasireotide Alone or Combined with Cabergoline in Patients with Cushing’s Disease. Expert Opin Emerg Drugs. 2015;20(3):463–70. doi:10.1517/14728214.2015.1047762.

84. van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW. Rapid reversal of acute psychosis in the Cushing syndrome with the corticotropin receptor antagonist mifepristone (RU 486). Ann Intern Med. 1991;114(2):143–4.

85. Carmichael JD, Fleseriu M. Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine. 2013;44(1):20–32. doi:10.1007/s12020-012-9486-1.

86. Castinetti F, Fassnacht M, Johansen T, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Pico A, Ouzounian S, Young J, Hahner S, Brue T, Albolito B, Conte-Devolx B. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol. 2009;160(3):303–10. doi:10.1530/EJE-08-0998.

87. Katsnelson L, Loriaux DL, Feldman D, Braundt GD, Schengart DE, Gross C. Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol (Oxf). 2014;80(4):562–9. doi:10.1111/cen.12332.

88. Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C. Changes in plasma ACTH levels and corticophorin tumor size in patients with Cushing’s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab. 2014;99(10): 3718–27. doi:10.1210/jc.2014-1843.

89. Fein HG, Vaughan 3rd TB, Kushner H, Cram D, Nguyen D. Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEMMSC study and long-term extension. BMC Endocr Disord. 2015;15:63. doi:10.1186/s12902-015-0059-5.
109. Schwartz SL, Rendell M, Ahmann AJ, Thomas A, Arauz-Pacheco CJ, Welles BR. Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase Ia multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther. 2008;30(6):1081–8. doi:10.1016/j.clinthera.2008.05.021.

110. Salvatori R, DelConte A, Geer EB, Kozioł T, Jorkaś D. An Open-Label Study to Assess the Safety and Efficacy of Levoketokonazole (COR-003) in the Treatment of Endogenous Cushing’s Syndrome. Adrenal Tumors, Glucocorticoid Regulation and Action. San Diego. 2015. FRI-376.

111. Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A. 2011;108(20):8414–9. doi:10.1073/pnas.1018091108.

112. Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, Melmed S. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease. J Clin Endocrinol Metab. 2015;100(7):2557–64. doi:10.1210/jc.2015-1606.

113. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holtsboer F, Grossman AB, Stalla GK, Arzt E. Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology. 2006;147(9):4438–44. doi:10.1210/en.2006-0414.

114. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontecorvi A, Cavagnini F. Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab. 2012;97(10):3577–83. doi:10.1210/jc.2012-2328.

115. Vilar L, Albuquerque JL, Lyra R, Trovao Diniz E, Rangel Filho F, Gadelha P, The AC, Ibiapina GR, Gomes BS, Santos V, Melo da Fonseca M, Fassao Viana K, Lopes KS, Araujo D, Naves L. The role of isotretoin therapy for Cushing’s disease: results of a prospective study. Int J Endocrinol. 2016;2016:8173182. doi:10.1155/2016/8173182.

116. Fukuoka H, Cooper Q, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011;121(12):4712–21. doi:10.1172/JCI60417.

117. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki K, Saeki Y, Tanaka K, Wieland T, Fassnacht M, Komada M. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet. 2015;47(1):31–8. doi:10.1038/ng.3166.

118. Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, Fukushima N, Okada M, Nishio H, Takeuchi Y, Komada M, Takeshita A, Yamada S. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing’s disease. Eur J Endocrinol. 2016;174(2):213–26. doi:10.1530/EJE-15-0689.

119. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94(4):1118–24. doi:10.1210/jc.2008-2101.

120. de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev Endocr Metab Disord. 2009;10(2):91–102. doi:10.1007/s11154-008-9082-4.

121. Culler MD. Somatostatin-dopamine chimeric compounds: a novel approach to treatment of neuroendocrine tumors. Horm Metab Res. 2011;43(12):854–7. doi:10.1055/s-0031-1287769.

122. Halem HA. PP29-1: a novel somatostatin receptor antagonist subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94(4):1118–24. doi:10.1210/jc.2008-2101.

123. de Bruin C, Pereira AM, groups. In Vivo Suppression of Corticosterone in Rodent Models of Cushing’s Disease with a Selective, Peptide MC2 Receptor Antagonist. Pituitary Development and Neoplasia. Boston. 2016. OR29-26.

124. Halem HA. Novel Aspects of the HPA Axis Bench to Smartphone. Chicago. 2014. OR48-45.